Infinity Pharmaceuticals Inc.

Cambridge, MA, United States

Infinity Pharmaceuticals Inc.

Cambridge, MA, United States

Time filter

Source Type

Patent
Infinity Pharmaceuticals Inc. | Date: 2016-06-23

Provided herein is a process for the transfer-hydrogenation of ketone analogs of members of the jervine type of Veratrum alkaloids, such as cyclopamine. Also provided herein are novel ruthenium transfer-hydrogenation catalysts.


Solid forms of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphic forms, cocrystals, and amorphous forms thereof, and pharmaceutical compositions thereof.


Patent
Infinity Pharmaceuticals Inc. | Date: 2017-04-26

Provided herein is a method for preparing the compound


Patent
Infinity Pharmaceuticals Inc. | Date: 2016-04-22

Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof, wherein the variables R^(A), R^(B )and R^(C )are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.


Patent
Infinity Pharmaceuticals Inc. | Date: 2016-10-25

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein.


Patent
Infinity Pharmaceuticals Inc. | Date: 2017-01-25

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.


Patent
Infinity Pharmaceuticals Inc. | Date: 2017-07-12

The invention is directed to a method to reduce a C-C double bond of an enone of a steroidal compound to produce a mixture of beta ketone product and alpha ketone product, comprising treating a solution or suspension of the steroidal compound in a solvent with hydrogen gas in the presence of a catalyst and substituted pyridine.


Patent
Infinity Pharmaceuticals Inc. | Date: 2016-02-04

Polymorphs of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphs thereof, and pharmaceutical compositions thereof.


Patent
Infinity Pharmaceuticals Inc. | Date: 2016-02-25

Provided are processes for the synthesis of amino analogues from ketone starting materials.


Patent
Infinity Pharmaceuticals Inc. | Date: 2016-10-10

The invention provides derivatives of cyclopamine having the following formula:

Loading Infinity Pharmaceuticals Inc. collaborators
Loading Infinity Pharmaceuticals Inc. collaborators